Abstract

Lipodystrophy syndromes (LD) are a heterogeneous group of very rare congenital or acquired disorders characterized by a generalized or partial lack of adipose tissue. They are strongly associated with severe metabolic dysfunction due to ectopic fat accumulation in the liver and other organs and the dysregulation of several key adipokines, including leptin. Treatment with leptin or its analogues is therefore sufficient to reverse some of the metabolic symptoms of LD in patients and in mouse models through distinct mechanisms. Brown adipose tissue (BAT) thermogenesis has emerged as an important regulator of systemic metabolism in rodents and in humans, but it is poorly understood how leptin impacts BAT in LD. Here, we show in transgenic C57Bl/6 mice overexpressing sterol regulatory element-binding protein 1c in adipose tissue (Tg (aP2-nSREBP1c)), an established model of congenital LD, that daily subcutaneous administration of 3 mg/kg leptin for 6 to 8 weeks increases body temperature without affecting food intake or body weight. This is associated with increased protein expression of the thermogenic molecule uncoupling protein 1 (UCP1) and the sympathetic nerve marker tyrosine hydroxylase (TH) in BAT. These findings suggest that leptin treatment in LD stimulates BAT thermogenesis through sympathetic nerves, which might contribute to some of its metabolic benefits by providing a healthy reservoir for excess circulating nutrients.

Highlights

  • This article is an open access articleLipodystrophy (LD) is an acquired or congenital condition characterized by a partial or complete lack of adipose tissue [1]

  • We found that leptin-treated Lipodystrophy syndromes (LD) mice had higher body temperature than their saline-treated counterparts

  • This was associated with increased molecular markers of thermogenesis and sympathetic nerves in Brown adipose tissue (BAT)

Read more

Summary

Introduction

This article is an open access articleLipodystrophy (LD) is an acquired or congenital condition characterized by a partial or complete lack of adipose tissue [1]. Because of the lack of adipose tissue, several metabolically important distributed under the terms and conditions of the Creative Commons. Twice daily subcutaneous administration of recombinant leptin (metreleptin) to 9 patients mainly with acquired or congenital generalized LD for 10 days markedly reduced fasting plasma HbA1c and triglycerides as well as liver volume in association with improved insulin sensitivity and appetite suppression [5]. These findings were subsequently confirmed and extended in a larger, long-term study [6]. Leptin could exert additional metabolic benefits in LD through targeting various different tissues

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call